On March 2, 2026, Beam Therapeutics Inc. and Bio Palette Co., Ltd. mutually terminated their 2019 License Agreement due to Bio Palette's planned dissolution, with no future payments due. This activated a standby exclusive license from Kobe University to the Company for the same patent rights related to base editing for human disease treatments worldwide, excluding microbiome in Asia.
Key takeaways
Termination Date: March 2, 2026
License Agreement with Bio Palette dated March 27, 2019 terminated in entirety
Standby License Agreement with Kobe University and Bio Palette dated February 9, 2026 activated
Kobe University granted Company exclusive license to base editing patents previously via Bio Palette
Company's prior license: exclusive, royalty-bearing for human disease treatments worldwide (excl. microbiome in Asia)
Mutual release of claims; no future payments due under terminated agreements